The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2024

Filed:

Dec. 03, 2019
Applicant:

Innovative Cellular Therapeutics Co., Ltd., Shanghai, CN;

Inventors:

Chengfei Pu, Shanghai, CN;

Zhiyuan Cao, Shanghai, CN;

Lei Xiao, Shanghai, CN;

He Sun, Shanghai, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/30 (2013.01); C12N 15/86 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15043 (2013.01);
Abstract

Embodiments relate to a modified T cell comprising an antigen binding molecule, wherein expression and/or function of CDC42 in the modified cell has been enhanced. In embodiments, the modified cell has an increased level of cytokine release in response to an antigen that the antigen binding molecule binds as compared to a corresponding T cell that does not overexpress CDC42. In embodiments, the cytokine release comprises a cytokine release of IFNγ. In embodiments, the modified cell has an enhanced migration capability in response to a chemokine as compared to a corresponding T cell that does not overexpress CDC42.


Find Patent Forward Citations

Loading…